Risk and outcomes of COVID-19 in patients with multiple sclerosis.
COVID-19
Spain
incidence
multiple sclerosis
severe acute respiratory syndrome coronavirus 2
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
30
03
2021
received:
21
12
2020
accepted:
17
06
2021
pubmed:
22
6
2021
medline:
27
10
2021
entrez:
21
6
2021
Statut:
ppublish
Résumé
Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population. A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020. Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70-0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76-6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk. Patients with MS do not appear to have greater risks of SARS-CoV-2 infection or severe COVID-19 outcomes compared with the general population. The decision to start or continue disease-modifying treatment should be based on a careful risk-benefit assessment.
Sections du résumé
BACKGROUND AND PURPOSE
Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population.
METHODS
A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020.
RESULTS
Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70-0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76-6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk.
CONCLUSIONS
Patients with MS do not appear to have greater risks of SARS-CoV-2 infection or severe COVID-19 outcomes compared with the general population. The decision to start or continue disease-modifying treatment should be based on a careful risk-benefit assessment.
Identifiants
pubmed: 34152073
doi: 10.1111/ene.14990
pmc: PMC8444942
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3712-3721Informations de copyright
© 2021 European Academy of Neurology.
Références
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Am J Manag Care. 2012 Nov;18(11):735-42
pubmed: 23198715
Rev Neurol. 2019 Mar 16;68(6):229-235
pubmed: 30855706
Lancet. 2020 Mar 14;395(10227):846-848
pubmed: 32151325
Neurology. 2019 Mar 5;92(10):e1029-e1040
pubmed: 30770430
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Mult Scler. 2013 Feb;19(2):245-8
pubmed: 22546846
Mult Scler Relat Disord. 2020 Jun;41:102028
pubmed: 32220817
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
Mult Scler Relat Disord. 2020 Jul;42:102120
pubmed: 32315980
Neurol Neuroimmunol Neuroinflamm. 2020 May 15;7(4):
pubmed: 32414755
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Eur J Neurol. 2021 Nov;28(11):3712-3721
pubmed: 34152073
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
N Engl J Med. 2020 Jun 18;382(25):e102
pubmed: 32356626
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Mult Scler. 2020 Sep;26(10):1256-1260
pubmed: 32662742
Ann Neurol. 2020 Jun;87(6):794-797
pubmed: 32383812
J Neurol. 2020 May;267(5):1567-1569
pubmed: 32303837
Rev Neurol. 2020 May 1;70(9):329-340
pubmed: 32329046
Egypt J Neurol Psychiatr Neurosurg. 2020;56(1):44
pubmed: 32372857
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Int J Mol Sci. 2020 Apr 22;21(8):
pubmed: 32331343
CNS Drugs. 2015 Mar;29(3):229-44
pubmed: 25761739